Development of AAV-Based CRISPR/Cas9 Therapies for Correcting Duchenne Muscular Dystrophy by Targeted Genomic Integration

被引：0
|
作者：
Pickar-Oliver, Adrian [1 ]
Nelson, Christopher [1 ]
Bohning, Joel [1 ]
Gemberling, Matthew [1 ]
Bulaklak, Karen [1 ]
Gersbach, Charles A. [1 ]
机构：
[1] Duke Univ, Biomed Engn, Durham, NC USA
来源：
MOLECULAR THERAPY | 2019年 / 27卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
380
引用
收藏
页码：180 / 181
页数：2
相关论文
共 50 条
  • [1] Development of AAV-Based CRISPR/Cas9 Therapies for Correcting Duchenne Muscular Dystrophy by Targeted Genomic Integration
    Oliver, Adrian
    Nelson, Christopher
    Bohning, Joel
    Gilcrest, Kylie
    Gersbach, Charles
    MOLECULAR THERAPY, 2020, 28 (04) : 6 - 6
  • [2] Development of AAV-Based CRISPR/Cas9 Therapies for Correcting Duchenne Muscular Dystrophy by Targeted Genomic Integration
    Pickar-Oliver, Adrian
    Nelson, Christopher
    Bohning, Joel
    Gough, Veronica
    Perelli, Robin M.
    Landstrom, Andrew P.
    Gersbach, Charles A.
    MOLECULAR THERAPY, 2021, 29 (04) : 163 - 164
  • [3] Duchenne muscular dystrophy: CRISPR/Cas9 treatment
    Jerry R Mendell
    Louise R Rodino-Klapac
    Cell Research, 2016, 26 : 513 - 514
  • [4] Duchenne muscular dystrophy: CRISPR/Cas9 treatment
    Mendell, Jerry R.
    Rodino-Klapac, Louise R.
    CELL RESEARCH, 2016, 26 (05) : 513 - 514
  • [5] Applications of CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy
    Lim, Kenji Rowel Q.
    Yoon, Chantal
    Yokota, Toshifumi
    JOURNAL OF PERSONALIZED MEDICINE, 2018, 8 (04):
  • [6] Development of Nanoparticles to Deliver a CRISPR/Cas9 Therapy for Duchenne Muscular Dystrophy
    Emami, Michael R.
    Young, Courtney S.
    Ji, Ying
    Pyle, April D.
    Meng, Huan
    Spencer, Melissa J.
    MOLECULAR THERAPY, 2018, 26 (05) : 284 - 285
  • [7] Further development of a CRISPR/Cas9 platform for 60% of Duchenne muscular dystrophy patients
    Fernandez, Karla
    FASEB JOURNAL, 2017, 31
  • [8] A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9
    Sui, Tingting
    Lau, Yeh Siang
    Liu, Di
    Liu, Tingjun
    Xu, Li
    Gao, Yandi
    Lai, Liangxue
    Li, Zhanjun
    Han, Renzhi
    DISEASE MODELS & MECHANISMS, 2018, 11 (06)
  • [9] Correction of a common Duchenne muscular dystrophy mutation by CRISPR/Cas9 gene editing using homology-independent targeted integration
    Nicolau, S.
    Sarff, J.
    Vetter, T.
    Stephenson, A.
    Flanigan, K.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [10] Assessment of Immunomodulatory Regimens that Allow Systemic Redosing of an AAV-CRISPR/Cas9 Therapy for Duchenne Muscular Dystrophy
    Young, Courtney S.
    Gibbs, Elizabeth
    Marinov, Masha
    Emami, Michael
    Younesi, Shahab
    Bengtsson, Niclas
    Chamberlain, Jeffrey
    Pyle, April
    Spencer, Melissa
    MOLECULAR THERAPY, 2020, 28 (04) : 221 - 221
12345